Dr. Isaac Shariv strengthens transfer at the University Medical Center Göttingen
The newly established Technology Transfer Office (TTO) of the University Medical Center Göttingen (UMG) aims to translate and transfer medical science research into patients benefit in a sustainable and targeted manner. As a recognized expert with international experience, Dr. Isaac Shariv is heading the TTO since the beginning of July 2024. In addition, a Dean for Transfer and the UMG's own accelerator strengthen the UMG's transfer efforts.
From Lab to Society: The University Medical Center Göttingen (UMG) is strengthening its technology transfer team. Since July 1, 2024, Dr. Isaac Shariv is heading the newly founded Technology Transfer Office (TTO) of the UMG, which is set up as an independent institution in the Research and Teaching division. With his many years of experience as former Head of Technology Transfer at the renowned Weizmann Institute for Science in Rehovot, Israel, and at the University of Sydney, Australia, Shariv is a recognized expert in technology transfer. The aim of the TTO is to further develop the results of medical science research at the UMG directly for the benefit of patients worldwide. The path from the laboratory to new drugs and medical products as well as innovative treatment methods is to be accelerated through close cooperation between research and industry.
"We are delighted to recruit Dr. Isaac Shariv for the University Medical Center Göttingen. Our goal is to significantly accelerate technology transfer in the coming years for patients benefit. We are relying on the extensive experience of Dr. Isaac Shariv, a worldwide known Tech Transfer expert, who led high league research centers to successfully translate their research for patients benefit,” says Prof. Dr. Wolfgang Brück, Chief Executive Officer of the UMG. “We, at UMG, want to see our excellent science translated to good medicines, treatments and products. The interaction between drug development, pharmaceutical industry and the academic research brings science and translation to its best potential.”
“It is exciting to join the University Medical Center Göttingen at this particular time. The translation of medical research results and inventions into health products and services for the benefit of the public is at the highest priority at UMG. This important task is receiving the closest attention by UMG management and by industry partners and government. I am looking forward to being part of the excellent team devoted to technology transfer at UMG”, says Dr. Isaac Shariv, Head of TTO.
In addition to TTO, the UMG has already established two other important components in recent months to accelerate technology transfer. A Dean for Transfer strengthens the Faculty of Medicine since beginning of March 2024. In her new role, Prof. Dr. Elisabeth Zeisberg will facilitate the transfer of research results for the benefit of people. Scientists at the UMG will receive concrete help in transfer projects and applying for funding to further develop theirs. A long-standing researcher and successful founder in the field of biotechnology herself, last year she founded the company Avocet Bio, which is developing an antiviral platform technology.
The third pilar of enhancing technology transfer is accelerating the inventions and directing the research to the next steps towards regulatory approval plausibility. An UMG Accelerator is established and it involves industry specialists in research projects from early stage. The accelerator is led by Dr. Liat Nissimov Brück PhD, MBA with 25 years of experience in pharma industry. The goals are more startup companies formed, big pharma involvement and more inventions licensed. The UMG believes in educating young researchers (MSc, PhD and MD). This year we started teaching drug development and the relevant processes involved in a special course.
About the person
Isaac Shariv was born in Jaffa, Israel. He holds a PhD degree in Physics from the Weizmann Institute of Science and a Master of Business Administration from Tel Aviv University. From 1994 to 2000, he worked as CEO at El-Mul Technologies Ltd in Rehovot (now part of Exosens, France), a technology company that develops and manufactures detectors for charged particles. This was followed by a CEO position until 2006 at the Yeda Research and Development Company Ltd in Rehovot, the technology transfer company of the Weizmann Institute of Science, which is a leader in the field of technology transfer from universities to industry. From 2006 to 2009, he was Managing Director at Sydnovate, the commercialization arm of the University of Sydney in Australia. In 2009, he returned to the Weizmann Institute of Science in Israel as Vice President for Administration and Finance. Since 2012, he has been CEO of Weizmann Institute of Science Assets and Development (Mul Nof) Ltd. in Rehovot. The company manages and develops the Weizmann Institute's asset portfolio. Isaac Shariv was a member of the board of various companies and organizations, in the technology, high tech and educational sectors. He was granted five patents in the fields of electro-optics and particle detection and published twelve scientific papers in the fields of physics, electro-optics and molecular biology.
Wissenschaftlicher Ansprechpartner:
University Medical Center Göttingen, Georg-August-University
Technology Transfer Office (TTO)
Dr. Isaac Shariv
Robert-Koch-Str. 40, 37075 Göttingen
Phone +49 551 / 39-61004
isaac.shariv@med.uni-goettingen.de
Die semantisch ähnlichsten Pressemitteilungen im idw
